In unadjusted analyses , treatment with upstream tirofiban vs eptifibatide was associated with similar rates of major bleeding ( 5.8 % vs 6.5 % , P = .39 ) and nonsignificantly lower rates of MACE ( 6.1 % vs 7.6 % , P = .06 ) and NACE ( 10.6 % vs 12.6 % , P = .06 ) .